Loading...
XNASKPTI
Market cap90mUSD
Jan 13, Last price  
0.67USD
1D
0.36%
1Q
-16.56%
Jan 2017
-92.36%
IPO
-95.50%
Name

Karyopharm Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:KPTI chart
P/E
P/S
0.58
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
15.00%
Rev. gr., 5y
36.93%
Revenues
146m
-7.03%
152,000634,000387,000229,000250,000154,0001,605,00030,336,00040,893,000108,085,000209,819,000157,074,000146,033,000
Net income
-143m
L-13.43%
-10,311,000-15,888,000-33,947,000-75,777,000-118,181,000-109,577,000-128,984,000-178,407,000-199,590,000-196,273,000-124,088,000-165,291,000-143,099,000
CFO
-93m
L-38.00%
-8,549,000-15,509,000-30,290,000-51,447,000-94,029,000-84,391,000-73,717,000-159,117,000-190,822,000-160,234,000-107,116,000-149,554,000-92,723,000
Earnings
Feb 26, 2025

Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
IPO date
Nov 06, 2013
Employees
385
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
146,033
-7.03%
157,074
-25.14%
Cost of revenue
275,573
299,276
Unusual Expense (Income)
NOPBT
(129,540)
(142,202)
NOPBT Margin
Operating Taxes
323
369
Tax Rate
NOPAT
(129,863)
(142,571)
Net income
(143,099)
-13.43%
(165,291)
33.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,124
193,738
BB yield
-1.14%
-69.60%
Debt
Debt current
6,616
2,872
Long-term debt
179,805
179,074
Deferred revenue
132,718
Other long-term liabilities
133,457
204,723
Net debt
(5,022)
(96,654)
Cash flow
Cash from operating activities
(92,723)
(149,554)
CAPEX
(118)
Cash from investing activities
7,940
(104,256)
Cash from financing activities
1,124
193,738
FCF
(119,273)
(156,401)
Balance
Cash
191,443
277,967
Long term investments
633
Excess cash
184,141
270,746
Stockholders' equity
(1,487,187)
(1,344,565)
Invested Capital
1,664,762
1,772,419
ROIC
ROCE
EV
Common stock shares outstanding
114,221
81,871
Price
0.87
-74.56%
3.40
-47.12%
Market cap
98,801
-64.51%
278,361
-42.45%
EV
93,779
181,707
EBITDA
(129,010)
(141,581)
EV/EBITDA
Interest
23,823
24,996
Interest/NOPBT